Treatment of cognitive disorders in depression caused by cerebrovascular pathology: the possibility of influencing acetylcholine neurotransmission

Maruta N.О.,Yavdak I.О.,Cherednyakova О.S.

Main
Publications
Treatment of cognitive disorders in depression caused by cerebrovascular pathology: the possibility of influencing acetylcholine neurotransmission

August 30, 2021

946

Neurology and Psychiatry

Keywords :

neuroprotective therapy

Specialities :

Neurology and Psychiatry

Resume

In order to assess the effectiveness of the use of the drug Cereglia^® (choline alfoscerate) in the complex treatment of depressive and cognitive disorders in patients with stage II dyscirculatory encephalopathy caused by atherosclerosis, a comprehensive clinical and psychodiagnostic examination was carried out (assessment of the depressive state according to the Hamilton scale; mnestic activity according to the method of memorizing ten words by A.R. Luria; cognitive functions according to the Montreal scale for the assessment of cognitive functions; the level of efficiency, concentration and stability of attention using the corrective Bourdon test; the severity of asthenic disorders according to the subjective scale for assessing asthenia (Multidimensional Fatigue Inventory) 60 patients with the indicated pathology. The results of the study prove the high efficiency of the use of neuroprotective therapy (Cereglia^®) in the complex therapy of patients. It has been shown that the inclusion of the drug Cereglia^® in therapy helps to reduce depressive disorders, improve cognitive functions (voluntary attention and mnestic functions), increase the level of work capacity and activity, which confirms the prospects of using the drug in the therapy of this category of patients.

References:

WHO (2015) World report on aging and health (rgnkc.ru/images/pdf_documets/VOZ_doklad_starenie.pdf). (In Rus.).
Vasenina E.E., Levin O.S., Sonin A.G. (2017) Current trends in the epidemiology of dementia and the management of patients with cognitive impairments. J. Neurol. Psychiatrist., 117(6–2): 87–95. DOI: 10.17116/jnevro20171176287-95. (In Rus.).
Gusev E.I., Bogolepova A.N. (2013) Cognitive impairment in cerebrovascular diseases. MEDpress-inform, Moscow, 176 р. (In Rus.).
Kruglov L.S., Meshandin I.A. (2012) Optimization of therapy for elderly patients with comorbidity of depression and psychoorganic disorders of vascular origin. Psychiatrist. Psychopharmacoter., 14(2): 40–45. (In Rus.).
Meshandin I.A. (2012) Dynamics of clinical characteristics and social functioning in the course of therapy in elderly patients with a combination of depressive disorder and psychoorganic disorders of vascular origin. Abstract of thesis. dis. … Cand. Med. Sci., St. Petersburg, 194 p. (In Rus.).
Odinak M.M., Emelin A.Yu., Lobzin V.Yu., Kolcheva Yu.A. (2009) Therapy for vascular cognitive disorders, RMJ, 20(359): 1295–1297. (In Rus.).
Taqui AM, Itrat A, Qidwai W, Qadri Z. Depression in the elderly: does family system play a role? A cross-sectional study. BMC Psychiatry. 2007; 7: 7–57.
Voznesenskaya T.G. (2009) Depression in old age. Consilium medicum, 11(2): 74–79. (In Rus.).
Chistik T. (2015) Cholinergic strategy in the treatment of cognitive impairment in aging. Int. Neurol. J. ,2(72): 147–152. (In Rus.).
Alexopoulos G.S., Murphy C.F., Gunning-Dixon F.M. et al. (2008) Microstructural white matter abnormalities and remission of geriatric depression. Am. J. Psychiatr., 165: 238–244.
Cumming T.B., Bernhardt J., Linden T. (2011) The Montreal cognitive assessment short cognitive evaluation in a large stroke trial. Stroke, 42: 2642–2644.
Zakharov V.V., Yakhno N.N. (2005) Cognitive disorders in old and old age. Method. manual. for doctors. Moscow, 71 p. (In Rus.).
Maruta N.O., Panko T.V., Cherednyakova O.S. (2008) Clinical and psychopological features of depression in the elderly. Int. Psychiatrist. Psychotherapist. Psychoanalyst. J., 2(1–2): 24–27. (In Ukr.).
Maruta N.O., Yaroslavtsev S.O. (2020) Principles of therapy of cognitive disorders in depressive disorders. UMJ, 6(140). DOI: 10.32471/umj.1680-3051.140.193326. (In Ukr.).
Fedchenko V.Yu. (2018) Comprehensive system of rehabilitation of depressive disorders. Visn. Sci. Res., 3: 89–94. (In Ukr.).
Schaffer A., McIntosh D., Goldstein B.I. et al.; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force (2012) The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann. Clin. Psychiatr.,24(1): 6–22.
Morimoto S.S., Alexopoulos G.S. (2013) Cognitive deficits in geriatric depression: clinical correlates and implications for current and future treatment. Psychiatr. Clin. North Am., 36(4): 517–531. DOI: 10.1016/j.psc.2013.08.002.
Lorenzetti V., Allen N.B., Fornito A. et al. (2009) Structural brain abnormalities in major depressive disorder: A selective review of recent MRI studies. J. Affect. Dis., 117: 1–17.
Batysheva T.T., Zaitsev K.A., Kamchatnov P.R. et al. (2011) The efficacy of choline alfoscerate (gliatilin) for mild cognitive impairment of vascular origin. S.S. Korsakov J. Neurol. Psychiatrist., 8: 29–32. (In Rus.).
Bachinskaya N.Yu., Kopchak O.O. (2014) Cholinergic strategy in the treatment of cognitive impairment in elderly and senile patients. Int. Neurol. J., 2(64). (In Rus.).
Mikhailova N.M. (2016) The use of Gliatilin in hospital treatment of elderly patients with dementia. Psychiatry, 1: 47–63. (In Rus.).
Muratorio A., Bonuccelli U., Nuti A. et al. (2014) Нейротропный подход к лечению мультиинфарктной деменции с использованием холина альфосцерата. Междунар. неврол. журн., 3(65): 10. https://medi.ru/info/3046/
Hamilton M. (1967) Development of a rating scale for primary depressive illness. Br. G. Soc. Clin. Psychol., 6: 278–296.
Bueno-Notivola J.,Gracia-Garcíaa P., Olayab B. et al. (2021) Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies. Int. J. Clin. Health Psychol., 21(1): 100196. DOI: 10.1016/j.ijchp.2020.07.007
Nasreddine Z.S., Phillips N.A. et al. (2005) The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool for Mild Cognitive Impairment. J. Am. Geriatr. Soc., 53(4): 695–699.
Correction test (Bourdon test) (1995) Almanac of psychological tests. Moscow, 107–111. (In Rus.).
Bizyuk A.P. (2005) Compendium of Neuropsychological Research Methods. St. Petersburg, Rech, 400 p. (In Rus.).
Smets E.M., Garssen B., Bonke B., De Haes J.C. (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosomatic Res., 39(3): 315–325. DOI: 10.1016/0022-3999(94)00125-o.